12:00 AM
 | 
Sep 10, 2007
 |  BioCentury  |  Product Development

HAE results

HAE results

Company Product Data Status
Dyax DX-88 yeast-derived recombinant plasma kallikrein inhibitor Ph III EDEMA3, n=72: Symptom improvement at 4 hrs: significant vs. placebo (p=0.021); also significant on secondary endpoints of reduction in symptom burden at 4 hrs and time to significant improvement...

Read the full 249 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >